Zylox-Tonbridge Medical Technology Co., Ltd. (ZYLOXTB) released its Monthly Return for the period ended 31 October 2026, detailing a modest share repurchase and updated equity statistics.
Authorised capital remains unchanged • The company’s registered share capital held steady at 344.13 million ordinary shares—336.35 million H-shares and 7.78 million unlisted domestic shares—each with a par value of RMB 1.
Issued share movements • Outstanding H-shares (excluding treasury) declined by 0.05% to 322.06 million following the repurchase of 159,500 shares on 13 May 2026 that were transferred to treasury. • Total issued shares, including treasury, were unchanged at 336.35 million.
Rising treasury position • Treasury stock increased to 14.29 million H-shares, equivalent to 4.25% of the company’s total issued shares, up from 14.13 million a month earlier.
Public float intact • Management confirmed compliance with the Main Board’s minimum 25% public-float requirement for the H-share class.
Equity incentive capacity • The 2025 Share Incentive Scheme shows 400,000 outstanding options, while 17.42 million shares remain available for future grants. • Under the Share Award Scheme adopted on 19 December 2024, up to 611,939 shares may still be issued or transferred from treasury.
Domestic shares stable • The unlisted domestic share count was unchanged at 7.78 million.
No warrants, convertibles or other capital-raising instruments were reported during the month. Overall, October’s activity underscores Zylox-Tonbridge’s ongoing share repurchase strategy while maintaining regulatory float and incentive flexibility.
Comments